Effect of Remimazolam or Propofol Combined With Esketamine on Anesthesia and Early Perioperative Neurocognitive Disorders in Patients Undergoing Thoracoscopic Partial Lung Resection: A Randomized Clinical Trial [0.03%]
瑞米扎宗或丙泊酚联合艾司氯胺酮对胸腔镜肺部分切除术患者麻醉及术后早期神经认知障碍的影响：一项随机临床试验
Wen Yuan,Xiao Liang,RuJin Zhang et al.
Wen Yuan et al.
Purpose: This study aimed to evaluate the effects of remimazolam in conjunction with esketamine on anesthesia and the incidence of early perioperative neurocognitive disorders (PNDs) in patients undergoing thoracoscopic p...
Dispensary Budtender Guidance Versus Clinician Consensus: A Comparative Study of Medical Cannabis Advice [0.03%]
药房大麻服务员的指导与临床医生的意见一致性的比较研究：医学大麻建议的比较研究
Marshall M Mee,Jesus Maldonado,Jenna M Jimenez et al.
Marshall M Mee et al.
Purpose: Medical cannabis (MC) patients frequently rely on budtenders, dispensary staff without formal medical training, for therapeutic guidance. This study examined whether budtender guidance aligns with that of MC clin...
Effect of Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) on Neuropsychiatric Outcomes: A Systematic Review and Meta-Analysis [0.03%]
胰高糖素样肽1受体激动剂对神经精神结局影响的系统评价和meta分析
Ishraq Choudhury,John Headly Ward,Sahana Mahesh et al.
Ishraq Choudhury et al.
Purpose: Type 2 diabetes mellitus (T2D) is associated with an increased burden of neuropsychiatric disorders, including cognitive decline, affective disorders, and substance use disorders. Glucagon-like peptide-1 receptor...
Antipsychotic Treatment Pathways, Real-World Adherence, Healthcare Resource Utilization, and Healthcare Costs Among Patients With Schizophrenia Treated With Once-Monthly, Once-Every-Three-Months, and Once-Every-Six-Months Paliperidone Palmitate in the United States [0.03%]
美国多巴胺D2受体拮抗剂棕榈酸帕利哌酮每月一次、每三个月一次和每六个月一次给药方案的精神分裂症患者的治疗路径、真实世界依从性、医疗资源利用及医疗费用研究
Laura Morrison,Dominic Pilon,Arthur Voegel et al.
Laura Morrison et al.
Purpose: Patients with schizophrenia can initiate once-every-6-months paliperidone palmitate (PP6M), currently the longest dosing interval long-acting injectable (LAI) antipsychotic (AP), following adequate treatment with...
Paul Beninger
Paul Beninger
Pharmacoeconomic Impact of Purchasing Off-Label Drugs in Tunisia: Case Study of Pembrolizumab (Keytruda®) [0.03%]
突尼斯购买非适应症用药的药事经济影响：帕博利珠单抗(Keytruda®)案例研究
Iheb Tbib,Sarah Zerei,Sameh Jellali et al.
Iheb Tbib et al.
Purpose: Access to medicines is a universal right guaranteed by Tunisian law and is ensured through 2 pathways: Marketing Authorization (MA) for products approved for national commercialization, or the off-label drug purc...
Charissa W Kam,Cameron J McKinzie,Jennifer L Goralski
Charissa W Kam
Highly effective modulator therapy (HEMT) has been life-changing for many living with cystic fibrosis (CF), a genetic disease affecting all races and ethnicities. With diagnoses now occurring in utero for many patients, prenatal treatment o...
Pesticides in Cannabis: The Need for Evidence to Inform Policy and Protect Patients [0.03%]
农药与大麻类药物：需要证据来指导政策制定和保护患者利益
Tyler D Watson,Nicholas C Glodosky,Tholo J Johnson et al.
Tyler D Watson et al.
Drawing from an interdisciplinary synthesis of microbiology, chemistry, osteopathic medicine, psychology, environmental health, and regulatory policy, this commentary highlights the increasingly pertinent issue of pesticide residues in stat...
Response to Letter to the Editor: Commending the Feasibility of CYP2C19 Pharmacogenetic Testing in Personalized Antiplatelet Therapy-Insights and Perspectives [0.03%]
关于《编辑部来信》的回应：颂扬CYP2C19药物基因组学检测在个性化抗血小板治疗中的可行性——见解与观点
Rania Abdel-Latif,Wadha Al Muftah,Shaban Mohammed et al.
Rania Abdel-Latif et al.
Corrigendum to "LYNKUETⓇ (Elinzanetant)" [Clin Ther. 2026;48:208-209] [0.03%]
“LYNKUETⓇ（elinzanetant）”的勘误启事[Clin Ther. 2026;48:208-209]
Paul Beninger
Paul Beninger
Published Erratum
Clinical therapeutics. 2026 Mar 6:S0149-2918(26)00039-1. DOI:10.1016/j.clinthera.2026.02.005 2026